Dako makes companion diagnostics available to all types of pathology laboratories by launching new breast cancer test for bright field microscopy
(Thomson Reuters ONE) -
Dako, a Danish based world leader in tissue-based cancer diagnostics, today
launches a new member of its companion diagnostics product portfolio, the HER2
CISH pharmDx(TM) Kit, in Europe, Canada and a number of other countries. The new
diagnostic test is specifically developed as an aid in the assessment of breast
cancer patients for whom treatment with Herceptin(®) is being considered. It
allows pathologists to perform validated gene tests with the use of readily
available bright field microscopes.
The new HER2 CISH pharmDx(TM) Kit from Dako opens the way to molecular testing
in breast cancer diagnosis for a wider group of pathology laboratories, offering
a number of benefits to the pathologists in the laboratories.
"HER2 CISH pharmDx(TM), with its convenience for bright field technology, is
likely to win the wide appeal of pathologists, who are increasingly engaged in
diagnostic biomarking of breast cancer," says Bharat Jasani, Professor, Head of
Pathology, Department of Medical Genetics, Haematology & Pathology at Cardiff
University School of Medicine in the UK.
Traditionally, molecular testing requires the use of a fluorescence microscope
which is not readily available in all pathology laboratories. With the HER2 CISH
pharmDx(TM) Kit, however, the pathologist can use a traditional bright field
microscope to determine whether the patient is likely to benefit from receiving
treatment with Herceptin®.
"Dako CISH staining is very reliable. Whereas FISH requires an expensive
fluorescence microscope and a dark room, Dako dual color CISH is now feasible in
any diagnostic or pathology laboratory. In my opinion, this technology will
immensely benefit molecular testing in pathology laboratories," says J. Han
J. M. van Krieken, MD, PhD and Professor of Tumor Pathology at Nijmegen Centre
for Molecular Life Sciences in the Netherlands.
The dual color assay is being recommended by national guidelines rather than
single color tests, as both the gene and reference signals can be seen on the
same slide. The HER2 scoring, which is supported by a standardized and validated
protocol, is considerably faster with a CISH test than with a FISH test.
Moreover, with the HER2 CISH pharmDx(TM) Kit, test slides can be stored for
reevaluation at a later point in time.
"We have seen how other Dako HER2 pharmDx(TM) products have helped many women
with breast cancer by determining the right treatment for their disease. This
latest addition to our pharmDx(TM) portfolio of products supports Dako's mission
to fight cancer by assisting pathologists in generating even more accurate,
objective and reproducible diagnostic results to the benefit of cancer
patients," says Lars Holmkvist, CEO of Dako.
A recent study comprising 365 breast cancer patients shows there is 97.7 percent
concordance between HER2 CISH pharmDx(TM) and a HER2 FISH test. This is well
over the threshold of 95 percent recommended by the American Society of Clinical
Oncology (ASCO) and the College of American Pathologists (CAP).
HER2 CISH pharmDx(TM) Kit has received the CE-IVD label. It is available as of
today in Europe, Canada and a number of other countries.
About the HER2 CISH pharmDx(TM) Kit
HER2 CISH pharmDx(TM) Kit is a dual color chromogenic assay designed to
quantitatively determine HER2 gene amplifications in breast cancer tissue
specimens, using bright field microscopes. HER2 CISH pharmDx(TM) Kits are
indicated to aid the assessment of patients for whom Herceptin(TM) treatment is
being considered. In a fraction of patients (25-30%) with breast cancer, the
HER2 gene is amplified.
Herceptin® was rationally developed to specifically target HER2-positive breast
cancers. Demonstration of high HER2 overexpression or gene amplification is
essential for treatment with Herceptin(TM). Clinical studies(1) have shown that
breast cancer patients whose tumors have high HER2 receptor overexpression
and/or amplification benefit most from Herceptin®.
About pharmacodiagnostics testing and personalized medicine
Pharmacodiagnostic testing is performed in order to determine whether or not
apatient is likely to respond to a given treatment. This testing is a
prerequisite for the implementation of personalized medicine.
The idea behind personalized medicine is that identification of the individual's
biological characteristics makes it possible to determine whether the patient
will respond to drug treatments or not. In some cases this can be determined by
a blood test, but in most cases sophisticated protein or gene tests such as
those from Dako are required.
Media contact
Lene Christoffersen
+4540748782
lene.christoffersen(at)dako.com
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make precise diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1000 people and being present in more than 80 countries, Dako covers essentially
all of the anatomic pathology markets globally. Dako is owned by a private
equity fund, EQT.www.dako.com
[HUG#1459904]
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 08.11.2010 - 10:45 Uhr
Sprache: Deutsch
News-ID 48513
Anzahl Zeichen: 6308
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako makes companion diagnostics available to all types of pathology laboratories by launching new breast cancer test for bright field microscopy"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
